Charles Blanke

Summary

Affiliation: Oregon Health and Science University
Country: USA

Publications

  1. ncbi request reprint A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma
    C D Blanke
    Department of Medicine, Oregon Health and Science Uniiversity, Portland 97201, USA
    Ann Oncol 12:1575-80. 2001
  2. ncbi request reprint A phase I study of 5-fluorouracil, leucovorin, and celecoxib in patients with incurable colorectal cancer
    Charles D Blanke
    Oregon Health and Science University Cancer Institute, Portland, OR, USA
    Prostaglandins Other Lipid Mediat 75:169-72. 2005
  3. ncbi request reprint State-of-the art therapy for gastrointestinal stromal tumors
    Charles D Blanke
    Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon 97201, USA
    Cancer Invest 23:274-80. 2005
  4. ncbi request reprint Chemotherapy with cyclooxygenase-2 inhibitors in the treatment of malignant disease: pre-clinical rationale and preliminary results of clinical trials
    Charles D Blanke
    Oregon Health and Science University, Portland, Oreg, USA
    Prog Exp Tumor Res 37:243-60. 2003
  5. ncbi request reprint Role of COX-2 inhibitors in cancer therapy
    Charles Blanke
    Oregon Health Science University, 3181 Southwest Sam Jackson Park Rd, Portland, OR 97201, USA
    Cancer Invest 22:271-82. 2004
  6. doi request reprint Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT
    Charles D Blanke
    Oregon Health and Science University Cancer Center and Portland Veterans Affairs Hospital, Portland, OR, USA
    J Clin Oncol 26:620-5. 2008
  7. ncbi request reprint Gastrointestinal stromal tumors
    C D Blanke
    Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health and Science University and Portland Veterans Affairs Medical Center, MC OP28, 3181 S W Sam Jackson Park Road, Portland, OR 97201, USA
    Curr Treat Options Oncol 2:485-91. 2001
  8. doi request reprint Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033
    Charles D Blanke
    Oregon Health and Science University Cancer Institute, 3181 SW Sam Jackson Park Rd, L 586, Portland, OR 97239, USA
    J Clin Oncol 26:626-32. 2008
  9. ncbi request reprint A double-blind placebo-controlled randomized phase III trial of 5-fluorouracil and leucovorin, plus or minus trimetrexate, in previously untreated patients with advanced colorectal cancer
    C D Blanke
    Oregon Health and Science University, Portland 97201, USA
    Ann Oncol 13:87-91. 2002
  10. ncbi request reprint Current management of GIST
    Charles Blanke
    Oregon Health and Science University, USA
    Clin Adv Hematol Oncol 2:280, 283. 2004

Detail Information

Publications40

  1. ncbi request reprint A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma
    C D Blanke
    Department of Medicine, Oregon Health and Science Uniiversity, Portland 97201, USA
    Ann Oncol 12:1575-80. 2001
    ..A phase II study testing the safety and efficacy of irinotecan (CPT-11). 5-fluorouracil (5-FU), and leucovorin (LCV) was conducted in patients with advanced gastric adenocarcinomas...
  2. ncbi request reprint A phase I study of 5-fluorouracil, leucovorin, and celecoxib in patients with incurable colorectal cancer
    Charles D Blanke
    Oregon Health and Science University Cancer Institute, Portland, OR, USA
    Prostaglandins Other Lipid Mediat 75:169-72. 2005
    ..5-FU and leucovorin did not affect COX-2 inhibition by celecoxib. Preliminary data suggest it is safe to combine celecoxib with standard chemotherapeutic agents, in treatment of patients with colorectal cancer...
  3. ncbi request reprint State-of-the art therapy for gastrointestinal stromal tumors
    Charles D Blanke
    Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon 97201, USA
    Cancer Invest 23:274-80. 2005
    ..Questions remain about the optimal dose of imatinib, whether to continue drug in the setting of progressive disease, and how best to prevent or overcome resistance...
  4. ncbi request reprint Chemotherapy with cyclooxygenase-2 inhibitors in the treatment of malignant disease: pre-clinical rationale and preliminary results of clinical trials
    Charles D Blanke
    Oregon Health and Science University, Portland, Oreg, USA
    Prog Exp Tumor Res 37:243-60. 2003
  5. ncbi request reprint Role of COX-2 inhibitors in cancer therapy
    Charles Blanke
    Oregon Health Science University, 3181 Southwest Sam Jackson Park Rd, Portland, OR 97201, USA
    Cancer Invest 22:271-82. 2004
  6. doi request reprint Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT
    Charles D Blanke
    Oregon Health and Science University Cancer Center and Portland Veterans Affairs Hospital, Portland, OR, USA
    J Clin Oncol 26:620-5. 2008
    ..We conducted a long-term analysis of patients treated on the trial, including patients followed during an extension phase, to evaluate survival, patterns of failure, and potential prognostic factors, including tumor mutational status...
  7. ncbi request reprint Gastrointestinal stromal tumors
    C D Blanke
    Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health and Science University and Portland Veterans Affairs Medical Center, MC OP28, 3181 S W Sam Jackson Park Road, Portland, OR 97201, USA
    Curr Treat Options Oncol 2:485-91. 2001
    ..Its use can serve as a paradigm for designing molecularly targeted therapies for other malignancies...
  8. doi request reprint Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033
    Charles D Blanke
    Oregon Health and Science University Cancer Institute, 3181 SW Sam Jackson Park Rd, L 586, Portland, OR 97239, USA
    J Clin Oncol 26:626-32. 2008
    ....
  9. ncbi request reprint A double-blind placebo-controlled randomized phase III trial of 5-fluorouracil and leucovorin, plus or minus trimetrexate, in previously untreated patients with advanced colorectal cancer
    C D Blanke
    Oregon Health and Science University, Portland 97201, USA
    Ann Oncol 13:87-91. 2002
    ..This trial was designed to demonstrate the safety and efficacy of TMTX/5-FU/LCV as first-line treatment in ACC...
  10. ncbi request reprint Current management of GIST
    Charles Blanke
    Oregon Health and Science University, USA
    Clin Adv Hematol Oncol 2:280, 283. 2004
  11. ncbi request reprint Celecoxib with chemotherapy in colorectal cancer
    Charles D Blanke
    Oregon Health Sciences University, Portland 97201, USA
    Oncology (Williston Park) 16:17-21. 2002
    ..Ongoing clinical trials are currently assessing the potential therapeutic role of COX-2 inhibitors in both prevention and treatment of a diverse range of human cancers...
  12. ncbi request reprint Gastrointestinal stromal tumors: imatinib and beyond
    Ian D Schnadig
    Oregon Health Sciences University Cancer Institute, 3181 Southwest Sam Jackson Park Road, Portland, OR 97239, USA
    Curr Treat Options Oncol 7:427-37. 2006
    ..With the identification of other downstream pathways, several other promising therapies are under current investigation either alone or in combination with imatinib and surgery...
  13. ncbi request reprint Gastrointestinal stromal tumors and the evolution of targeted therapy
    Rachel E Sanborn
    Oregon Health and Science University Cancer Institute, Portland, Oregon 97239, USA
    Clin Adv Hematol Oncol 3:647-57. 2005
    ..Whether this new era of targeted therapy will provide the same advances in more common malignancies will be determined only through the ongoing application and development of clinical trials...
  14. ncbi request reprint Current and future management of GIST
    Charles Blanke
    Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR 97239, USA
    Clin Adv Hematol Oncol 4:582-3. 2006
  15. pmc Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Gr
    Michael C Heinrich
    Division of Hematology Oncology, Department of Medicine and Cell and Developmental Biology, Portland Veterans Affairs Medical Center and Oregon Health and Science University Cancer Institute, Portland, OR 97239, USA
    J Clin Oncol 26:5360-7. 2008
    ..In previous studies, GIST genotype correlated with treatment outcome and optimal imatinib dosing...
  16. ncbi request reprint Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies
    Michael C Heinrich
    Department of Medicine, Division of Hematology Oncology, Oregon Health and Science University, USA
    J Clin Oncol 20:1692-703. 2002
    ..In this review, we discuss the rationale for and development of KIT tyrosine kinase inhibitors for the treatment of human malignancies...
  17. ncbi request reprint Pulmonary and intracerebral plasmacytomas in a patient without multiple myeloma: a case report
    Brandon Hayes-Lattin
    Division of Hematology and Medical Oncology, Oregon Health and Science University, The OHSU Cancer Institute, Portland, Oregon 97202, USA
    Am J Hematol 73:131-4. 2003
    ..Extramedullary plasmacytoma of the lung or brain parenchyma is rare. We report herein a case of extramedullary plasmacytoma involving both the lung and parenchymal brain. We review the literature, comparing and contrasting the current case...
  18. ncbi request reprint Molecular correlates of imatinib resistance in gastrointestinal stromal tumors
    Michael C Heinrich
    Division of Hematology Oncology, Department of Pathology, Oregon Health and Science University Cancer Institute, Oregon Health and Science University, Portland, OR, USA
    J Clin Oncol 24:4764-74. 2006
    ..In clinical studies, 75% to 90% of patients with advanced GISTs experience clinical benefit from imatinib. However, imatinib resistance is an increasing clinical problem...
  19. ncbi request reprint Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor
    Michael C Heinrich
    R and D 19 3710 SW US Veterans Hospital Rd, Portland, OR 97207, USA
    J Clin Oncol 21:4342-9. 2003
    ..The relationship between mutations in these kinases and clinical response to imatinib was examined in a group of patients with advanced GIST...
  20. ncbi request reprint Cyclooxygenase-2 inhibition in colorectal cancer: boom or bust?
    Rachel Sanborn
    Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR, USA
    Semin Oncol 32:69-75. 2005
    ....
  21. ncbi request reprint Outcome following surgical therapy for gastrointestinal stromal tumors
    Maneesh Gupta
    Department of Surgery, Oregon Health and Science University, Portland, Oregon 97239, USA
    J Gastrointest Surg 10:1099-105. 2006
    ..Mitotic index and the presence of metastases remain the primary predictors of postoperative survival. Complete surgical resection, even if multivisceral resection is required, is associated with improved survival...
  22. doi request reprint Evaluation of the tumor board as a Continuing Medical Education (CME) activity: is it useful?
    MaryClare Sarff
    Division of Surgical, Oregon Health and Science University, Portland
    J Cancer Educ 23:51-6. 2008
    ....
  23. ncbi request reprint Cancers of the gallbladder and biliary ducts
    Kevin Yee
    Department of Medicine, Oregon Health and Science University, Portland 97201, USA
    Oncology (Williston Park) 16:939-46, 949; discussion 949-50, 952-3, 956-7. 2002
    ..Of the newer agents, gemcitabine (Gemzar) holds the most promise in the treatment of these difficult malignancies...
  24. ncbi request reprint Gefitinib in colorectal cancer: if wishes were horses
    Charles D Blanke
    J Clin Oncol 23:5446-9. 2005
  25. ncbi request reprint The continuum of care: a paradigm for the management of metastatic colorectal cancer
    Richard M Goldberg
    Division of Hematology Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    Oncologist 12:38-50. 2007
    ....
  26. ncbi request reprint Epithelioid gastric stromal tumours of the antrum in young females with the Carney triad: a report of three new cases with mutational analysis and comparative genomic hybridization
    Abbas Agaimy
    Institute of Pathology, Klinikum N├╝rnberg, 90419 Nurnberg, Germany
    Oncol Rep 18:9-15. 2007
    ....
  27. ncbi request reprint Revisiting the Cancer and Leukemia Group B/Southwest Oncology Group 80405 Trial: a phase III trial of chemotherapy and biologic agents for patients with untreated advanced colorectal adenocarcinoma
    Alan P Venook
    Cancer and Leukemia Group B, University of California, San Francisco, CA 94115, USA
    Clin Colorectal Cancer 6:536-8. 2007
  28. ncbi request reprint NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines
    George D Demetri
    J Natl Compr Canc Netw 5:S1-29; quiz S30. 2007
    ....
  29. ncbi request reprint Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
    George D Demetri
    Dana Farber Cancer Institute and Harvard Cancer Center, Boston, MA 02115, USA
    N Engl J Med 347:472-80. 2002
    ..Imatinib mesylate, a selective tyrosine kinase inhibitor, has been shown in preclinical models and preliminary clinical studies to have activity against such tumors...
  30. ncbi request reprint Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib
    Petri Bono
    Department of Oncology, University Central Hospital of Helsinki, Helsinki, Finland
    Blood 103:2929-35. 2004
    ..1-259-fold). A high serum SCF/KIT ratio may increase SCF-induced cell signaling with prolonged imatinib treatment, at the time when imatinib treatment is withdrawn, and in patients whose GIST has wild-type receptors...
  31. ncbi request reprint Phase II study of preoperative paclitaxel/cisplatin with radiotherapy in locally advanced esophageal cancer
    Dong W Kim
    Department of Radiation Oncology, Vanderbilt University School of Medicine, Nashville, TN, USA
    Int J Radiat Oncol Biol Phys 67:397-404. 2007
    ..We evaluated paclitaxel-based induction chemoradiotherapy in patients with localized esophageal cancer to determine its feasibility, clinical response, pathologic response, and overall survival...
  32. ncbi request reprint Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials
    Daniel J Sargent
    North Central Cancer Treatment Group, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 23:8664-70. 2005
    ..A shorter-term end point providing convincing evidence to allow treatment comparisons could significantly speed the translation of advances into practice...
  33. ncbi request reprint Cancer and Leukemia Group B/Southwest Oncology Group trial 80405: a phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinoma
    Alan P Venook
    Cancer and Leukemia Group B, Department of Clinical Medicine, University of California San Francisco, 600 Divisadero Box 1770, San Francisco, CA 94115, USA
    Clin Colorectal Cancer 5:292-4. 2005
  34. ncbi request reprint Management of gastrointestinal stromal tumors in the imatinib era: selected case studies
    Robert S Benjamin
    Sarcoma Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas 77030, USA
    Oncologist 11:9-20. 2006
    ..The management of GIST in these cases required a coordinated, multidisciplinary approach involving medical oncologists, diagnostic radiologists, gastroenterologists, surgeons, and pathologists...
  35. ncbi request reprint Phase I trial of Orzel (UFT plus leucovorin), cisplatin, and radiotherapy in the treatment of potentially resectable esophageal cancer
    Karen L Tedesco
    Department of Oncology, Vanderbilt University School of Medicine and Veteran s Affairs Medical Center, Nashville, TN, USA
    Int J Radiat Oncol Biol Phys 61:1364-70. 2005
    ..This Phase I study was designed to determine the maximal tolerated dose and dose-limiting toxicity of UFT, leucovorin, and cisplatin when given with radiotherapy in the neoadjuvant treatment of resectable esophageal cancer...
  36. ncbi request reprint Targeted therapies in the treatment of colorectal cancer: what managed care needs to know
    Rowena N Schwartz
    University of Pittsburgh School of Pharmacy, 3501 Terrace St, 1104 Salk Hall, Pittsburgh, PA 15261, USA
    J Manag Care Pharm 10:S2-13; quiz S14-7. 2004
    ..This review is designed to explore the disease, its current treatment, the expanding field of antiangiogenic treatments, and the implications of these advances for the managed care patient...
  37. ncbi request reprint Phase II trial of gemcitabine plus irinotecan in patients with esophageal cancer: a Southwest Oncology Group (SWOG) trial
    Stephen K Williamson
    University of Kansas Medical Center, Kansas City, KS, USA
    Am J Clin Oncol 29:116-22. 2006
    ..Based on preclinical data suggesting a dose-dependent synergy between gemcitabine and irinotecan we have conducted a phase II trial in patients with advanced or metastatic esophageal carcinoma...
  38. ncbi request reprint Whither irinotecan?
    Charles D Blanke
    J Clin Oncol 23:4811-4. 2005
  39. ncbi request reprint Impact of the year 2000 Medicare policy change on older patient enrollment to cancer clinical trials
    Joseph M Unger
    Southwest Oncology Group Statistical Center, Seattle, WA, USA
    J Clin Oncol 24:141-4. 2006
    ..Recognition of this under-representation led to a change in Medicare policy in 2000 to include coverage of routine patient care costs of clinical trials. We conducted an updated analysis of accrual trends...
  40. ncbi request reprint Irinotecan and paclitaxel in metastatic adenocarcinoma of the esophagus and gastric cardia
    J Randolph Hecht
    UCLA School of Medicine, Los Angeles, California, USA
    Oncology (Williston Park) 17:13-5. 2003
    ..Preliminary data from a phase II trial of this regimen in adenocarcinomas of the gastroesophageal junction show good tolerability and promising activity (response rate of 27%), even in previously treated patients...